SaiyanMed Safety Rating & Test Results

As of 3 Sept 2026, Finnrick has published 14 independent lab tests of 3 peptides from SaiyanMed: 12 passed, 1 failed, and 1 was not classifiable (incomplete data) under the default public standard, Purity Focus (HPLC purity at least 99.5%, fill within ±35% of the label claim). The latest test is dated 21 Aug 2026.

Finnrick ratings are recency-weighted pass percentages: newer tests count more, and vendors with thin test histories are pulled toward the peer baseline for that peptide, so a single result cannot look too certain. Samples are analyzed by independent partner laboratories and the results are published by Finnrick Analytics, which does not sell peptides and does not accept payment to alter ratings. Corrections to published data are recorded at finnrick.com/corrections.

Purchased from SaiyanMed? Submit a sample to Finnrick for free independent lab testing — results are published publicly.

Are you SaiyanMed? Finnrick offers professional testing services and a public launch program for peptide vendors.

Interactive charts, prices, and test history for this page load with JavaScript; the facts above are from Finnrick's published test database.

SaiyanMed peptides tested by Finnrick, rated under the default public methodology.
PeptideFinnrick ratingLab testsLatest test
Retatrutide83%1021 Aug 2026
Tesamorelin50%25 Aug 2026
Tirzepatide81%217 Nov 2025